This company has been marked as potentially delisted and may not be actively trading. Gemphire Therapeutics (GEMP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock GEMP vs. NNVC, HILS, IBIO, TAOX, AEON, OBSV, AEZS, GRAY, NRBO, and CPHIShould you be buying Gemphire Therapeutics stock or one of its competitors? The main competitors of Gemphire Therapeutics include NanoViricides (NNVC), Hillstream BioPharma (HILS), iBio (IBIO), Synaptogenix (TAOX), AEON Biopharma (AEON), ObsEva (OBSV), Aeterna Zentaris (AEZS), Graybug Vision (GRAY), NeuroBo Pharmaceuticals (NRBO), and China Pharma (CPHI). Gemphire Therapeutics vs. Its Competitors NanoViricides Hillstream BioPharma iBio Synaptogenix AEON Biopharma ObsEva Aeterna Zentaris Graybug Vision NeuroBo Pharmaceuticals China Pharma NanoViricides (NYSE:NNVC) and Gemphire Therapeutics (NASDAQ:GEMP) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment. Do insiders and institutionals hold more shares of NNVC or GEMP? 10.3% of NanoViricides shares are owned by institutional investors. Comparatively, 17.5% of Gemphire Therapeutics shares are owned by institutional investors. 4.6% of NanoViricides shares are owned by company insiders. Comparatively, 22.7% of Gemphire Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more volatility & risk, NNVC or GEMP? NanoViricides has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500. Comparatively, Gemphire Therapeutics has a beta of 2.82, suggesting that its share price is 182% more volatile than the S&P 500. Does the media refer more to NNVC or GEMP? In the previous week, NanoViricides had 1 more articles in the media than Gemphire Therapeutics. MarketBeat recorded 1 mentions for NanoViricides and 0 mentions for Gemphire Therapeutics. NanoViricides' average media sentiment score of 0.50 beat Gemphire Therapeutics' score of 0.00 indicating that NanoViricides is being referred to more favorably in the media. Company Overall Sentiment NanoViricides Positive Gemphire Therapeutics Neutral Is NNVC or GEMP more profitable? NanoViricides' return on equity of -87.90% beat Gemphire Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets NanoViricidesN/A -87.90% -78.69% Gemphire Therapeutics N/A -419.70%-173.05% Which has higher valuation & earnings, NNVC or GEMP? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNanoViricidesN/AN/A-$8.29M-$0.70-2.26Gemphire TherapeuticsN/AN/A-$23.64MN/AN/A SummaryNanoViricides beats Gemphire Therapeutics on 5 of the 8 factors compared between the two stocks. Get Gemphire Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GEMP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GEMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GEMP vs. The Competition Export to ExcelMetricGemphire TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.06M$784.84M$5.52B$9.37BDividend YieldN/A4.84%4.74%4.12%P/E RatioN/A1.3728.9323.80Price / SalesN/A25.69440.5196.33Price / CashN/A19.5635.0756.59Price / Book1.136.688.255.54Net Income-$23.64M-$3.67M$3.25B$259.97M Gemphire Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GEMPGemphire TherapeuticsN/A$0.61+0.6%N/A-84.7%$9.06MN/A0.009NNVCNanoViricides0.6555 of 5 stars$1.70flatN/A-24.8%$27.32MN/A-2.3620HILSHillstream BioPharmaN/A$1.46-2.3%N/A-61.6%$25.70MN/A-2.031IBIOiBio1.313 of 5 stars$0.69-2.8%$5.00+624.7%-66.5%$11.40M$375K0.00100News CoverageTAOXSynaptogenixN/A$6.86+5.2%N/AN/A$9.06MN/A0.004AEONAEON Biopharma3.3463 of 5 stars$0.78-1.4%$360.00+46,172.5%-99.1%$8.80MN/A4.325Gap UpOBSVObsEvaN/AN/AN/AN/A$7.94MN/A0.0050News CoverageAEZSAeterna ZentarisN/A$3.90-1.5%N/A-35.5%$6.99M$2.37M-0.2620GRAYGraybug VisionN/A$3.80+3.0%N/A-34.4%$5.97MN/A-2.2027High Trading VolumeNRBONeuroBo PharmaceuticalsN/A$0.66-5.9%N/A-84.7%$5.72MN/A0.0010High Trading VolumeCPHIChina PharmaN/A$1.74-4.9%N/A-91.8%$5.68M$4.30M0.00250 Related Companies and Tools Related Companies NanoViricides Competitors Hillstream BioPharma Competitors iBio Competitors Synaptogenix Competitors AEON Biopharma Competitors ObsEva Competitors Aeterna Zentaris Competitors Graybug Vision Competitors NeuroBo Pharmaceuticals Competitors China Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GEMP) was last updated on 8/3/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredInvestigating the Most Controversial Stock on EarthTesla’s wild price swings may not be random after all. Hedge fund veteran Larry Benedict has uncovered a st...Brownstone Research | SponsoredThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredSell these "safe" blue chips immediatelyInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemphire Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Gemphire Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GEMP Stock Alerts